These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27586014)

  • 1. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
    Tomihara H; Eguchi H; Yamada D; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Surg Today; 2017 Feb; 47(2):218-226. PubMed ID: 27586014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
    Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
    Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
    Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
    Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y
    Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
    Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
    Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
    Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
    Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
    Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH
    Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
    Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
    Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.
    Takeuchi T; Mizuno S; Murata Y; Hayasaki A; Kishiwada M; Fujii T; Iizawa Y; Kato H; Tanemura A; Kuriyama N; Azumi Y; Usui M; Sakurai H; Isaji S
    Pancreas; 2019 Feb; 48(2):281-291. PubMed ID: 30629019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
    Motoi F; Satoi S; Honda G; Wada K; Shinchi H; Matsumoto I; Sho M; Tsuchida A; Unno M;
    J Gastroenterol; 2019 Feb; 54(2):194-203. PubMed ID: 30182219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
    Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
    In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
    Keane FK; Wo JY; Ferrone CR; Clark JW; Blaszkowsky LS; Allen JN; Kwak EL; Ryan DP; Lillemoe KD; Fernandez-Del Castillo C; Hong TS
    Am J Clin Oncol; 2018 Jun; 41(6):607-612. PubMed ID: 27740973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
    Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Uchikado Y; Arigami T; Uenosono Y; Mori S; Ueno S; Shinchi H; Natsugoe S
    Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pancreatic cancer showing complete pathological response to preoperative chemoradiotherapy-a case report].
    Tanizaki K; Hama N; Tomimaru Y; Eguchi H; Akita H; Wada H; Kawamoto K; Kobayashi S; Mori M; Doki Y; Nagano H
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1872-4. PubMed ID: 24393950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.